Valneva SE (VALN) Research & Development (2021 - 2026)
Valneva SE (VALN) posted Research & Development of -$17.8 million for Q1 2026, down 110.55% sequentially from $168.8 million in Q4 2025, and down 13.25% YoY from -$20.5 million in Q1 2025.
Valneva SE (VALN) Research & Development (2021 - 2026) Analysis & Trends
Valneva SE has reported Research & Development for 6 years, with the latest figure at -$17.8 million in Q1 2026.
- Quarterly Research & Development fell 13.25% year-over-year to -$17.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $99.3 million (up 29.26% YoY) and the FY2025 annual result came in at $99.3 million, up 23.74% from the prior year.
- Research & Development slipped to -$17.8 million in Q1 2026 per VALN's latest filing, from $168.8 million in the prior quarter.
- Over five years, Research & Development peaked at $184.0 million in Q4 2022 and troughed at -$33.3 million in Q2 2022.
- A 5-year average of $19.4 million and a median of -$17.7 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2025: Research & Development jumped 61.03% in 2023, then tumbled 53.82% in 2025.
- Over 5 years, Research & Development stood at $184.0 million in 2022, then sank by 40.28% to $109.9 million in 2023, then climbed by 19.35% to $131.1 million in 2024, then climbed by 28.75% to $168.8 million in 2025, then slumped by 110.55% to -$17.8 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered -$17.8 million, $168.8 million, and -$31.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn | 52.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 52.83 Mn |
| Mar 31, 2026 | -17.81 Mn |
| Dec 31, 2025 | 168.82 Mn |
| Sep 30, 2025 | -31.90 Mn |
| Jun 30, 2025 | -19.80 Mn |
| Mar 31, 2025 | -15.73 Mn |
| Dec 31, 2024 | 131.13 Mn |
| Sep 30, 2024 | -20.74 Mn |
| Jun 30, 2024 | -17.82 Mn |
| Mar 31, 2024 | -14.27 Mn |
| Dec 31, 2023 | 109.87 Mn |
| Sep 30, 2023 | -17.68 Mn |
| Jun 30, 2023 | -12.97 Mn |
| Mar 31, 2023 | -15.10 Mn |
| Dec 31, 2022 | 183.96 Mn |
| Sep 30, 2022 | -23.70 Mn |
| Jun 30, 2022 | -33.29 Mn |
| Mar 31, 2022 | -23.22 Mn |
| Dec 31, 2021 | 332.34 Mn |
| Sep 30, 2021 | -45.40 Mn |